Alzheimers disease is a progressive neurodegenerative condition that affects memory, thinking and behaviour. It's the most common form of dementia, accounting for 60-80% of dementia cases in Australia. The disease develops when proteins build up in the brain, forming plaques and tangles that damage and kill brain cells. Early symptoms include mild memory loss and difficulty with familiar tasks, while advanced stages can lead to severe cognitive decline and loss of physical function.
Australians should be aware that early detection can help with treatment planning. Common signs include misplacing items frequently, getting lost in familiar places, struggling with finances or bills, and asking repetitive questions. Personality changes and difficulty following conversations are also notable indicators that warrant a visit to your GP.
Age is the primary risk factor, with most cases occurring after age 65. Family history, genetics (particularly the APOE4 gene), cardiovascular disease, diabetes, and lifestyle factors all contribute to disease risk. Women are slightly more likely to develop Alzheimers than men, making regular health monitoring particularly important for older Australians.
Several medications are available through Australian pharmacies to help manage Alzheimers symptoms and potentially slow cognitive decline. These medicines work by affecting neurotransmitters in the brain or reducing protein accumulation.
Donepezil (Aricept) is widely prescribed in Australia and helps improve memory and thinking by increasing acetylcholine levels. Rivastigmine (Exelon) is another option available as tablets or patches. Galantamine (Reminyl) is also accessible through Australian pharmacies. These medications work best in mild to moderate stages and may improve symptoms or slow decline temporarily.
Memantine (Ebixa) is a medication that regulates glutamate activity in the brain. It's particularly useful for moderate to severe Alzheimers and can be used alongside cholinesterase inhibitors. This medication may help maintain cognitive function and delay symptom progression.
Aducanumab was recently approved in Australia for early-stage disease, targeting amyloid proteins directly. Lecanemab has shown promise in clinical trials for mild cognitive impairment and early dementia stages, helping slow cognitive decline in early-stage patients.
Beyond cognitive medications, Australian doctors prescribe medicines for associated symptoms including depression, anxiety, and sleep disturbances. Sertraline or citalopram may be recommended for mood issues, whilst melatonin or other sleep aids help with insomnia.
Parkinsons disease is a progressive neurological condition affecting movement, characterised by tremor, rigidity, and slow movement. It occurs when dopamine-producing neurons in the brain gradually die or become impaired. In Australia, approximately 70,000 people live with Parkinsons, with diagnosis typically occurring after age 60, though younger-onset cases exist.
The classic triad includes resting tremor (shaking at rest), muscle rigidity, and bradykinesia (slow movement). Secondary symptoms include postural instability, difficulty walking (gait disturbance), and a stooped posture. Non-motor symptoms are equally important, including depression, anxiety, sleep problems, and cognitive changes that significantly impact quality of life.
Early stages involve mild symptoms affecting one side of the body. Middle stages show increased motor difficulties and potential balance problems. Advanced Parkinsons can significantly impact quality of life, with complications including falls, swallowing difficulties, and dementia developing in some patients.
Australian pharmacies stock various medications designed to replace dopamine or enhance its effects in the brain. Treatment plans are individualised based on symptom severity and disease stage.
Madopar and Sinemet are the most commonly prescribed medications in Australia, combining levodopa with peripheral decarboxylase inhibitors. These remain the gold standard for symptom control, particularly for motor symptoms. They're most effective in early and middle disease stages.
Bromocriptine, pramipexole (Mirapex), and ropinirole (Requip) are available through Australian pharmacies. These medications mimic dopamine's effects and can be used alone in early stages or with levodopa later. They're particularly useful for managing tremor and rigidity.
Selegiline and rasagiline (Azilect) slow dopamine breakdown in the brain. Rasagiline is increasingly popular in Australia for its potential neuroprotective effects and once-daily dosing. These medications may help delay disease progression when used early.
Entacapone (Comtess) and tolcapone extend levodopa effectiveness by preventing its breakdown. These are typically added when levodopa's effects begin wearing off during the day, helping maintain symptom control throughout waking hours.
Anticholinergics like benztropine help tremor and rigidity, particularly in younger patients. Amantadine provides additional motor symptom relief and helps with medication-related side effects. Beta-blockers such as propranolol may reduce tremor when other treatments are insufficient.
Both Alzheimers and Parkinsons patients benefit significantly from non-pharmaceutical interventions alongside medications. These approaches enhance quality of life and may slow symptom progression.
Regular physical exercise improves motor function in Parkinsons and cognitive health in Alzheimers patients. Australians are encouraged to engage in walking, swimming, or tailored exercise programmes. Cognitive stimulation through puzzles, reading, and learning activities supports brain health. A Mediterranean-style diet rich in vegetables, fish, and olive oil shows protective benefits.
Speech pathology helps Parkinsons patients with voice projection and swallowing difficulties. Occupational therapy adapts home environments for safety. Physiotherapy maintains mobility and balance. For Alzheimers patients, cognitive rehabilitation and memory support programmes prove valuable in maintaining independence and quality of life.
Australian support organisations provide education, counselling, and respite care. Family members benefit from understanding disease progression and learning management strategies. Support groups connect patients and carers with others facing similar challenges, reducing isolation and providing practical advice.
Early diagnosis allows for better treatment planning and symptom management. Australians experiencing memory loss or movement changes should consult their GP promptly. Your pharmacist can also provide guidance on whether medical assessment is advisable.
GPs typically perform cognitive testing and physical examinations. Neurological referrals lead to specialist assessment including brain imaging (MRI or CT scans) and sometimes PET scans. For Parkinsons, diagnosis relies primarily on clinical evaluation, though DaTscan imaging occasionally confirms dopamine deficiency.
Once diagnosed, Australian specialists develop personalised treatment plans combining appropriate medications with lifestyle strategies. Regular monitoring adjusts medications as disease progresses. Alzheimers Australia and Parkinsons Australia provide information, support groups, and resources. These organisations help navigate aged care options, access government support, and connect with healthcare services available throughout Australia.
Australian pharmacies play a vital role in managing both conditions, providing medications, advice on usage, and support for patients and their families. Our team is available to discuss your specific situation and help you manage your health effectively.
